Aclidinium bromide/formoterol fumarate vs Umeclidinium/Vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline

Aclidinium bromide/formoterol fumarate · Duaklir Pressair

Rights held by Azurity Pharmaceuticals and partners; US product discontinued

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Partial signal

NCT01437397 · Phase 3 · completed

This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).

Reported efficacy

Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate (Week 24, morning pre-dose (trough)); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) (met)

Result source: NCT03022097

Umeclidinium/Vilanterol

Marketed by GlaxoSmithKline and partners

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT01777334 · Phase 3 · completed

The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.

Reported efficacy

Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)

Result source: NCT01777334

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAclidinium bromide/​formoterol fumarateUmeclidinium/​Vilanterol
Moderate or severe exacerbations, annualised rate—Not reported—Trial running · NCT06474039
Trough FEV1, change0.1 vs -0.0+0.1 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
0.2 vs 0.1vs TIO62.5/25 µg · wk 24 · n 400NCT01777334
3 other results
  • 0.1 vs -0.0 62.5/25 µg · wk 12.14 · n 224 · Phase 3 · primary NCT01899742
  • 0.2 vs 0.2 wk 12 · n 309 · Phase 3 · secondary NCT02487446
  • 0.2 vs 0.2 wk 12 · n 314 · Phase 3 · secondary NCT02487446
SGRQ total, change-6.6 vs -2.2−4.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
4 other results
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
—Trial running · NCT06474039
TDI focal score2.0 vs 0.6+1.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
  • 2.9 vs 2.1 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • 1.9 vs 1.9 wk 24 · n 353 · Phase 3 · secondary NCT01908140
—Trial running · NCT06474039

Moderate or severe exacerbations, annualised rate

Aclidinium bromide/​formoterol fumarate
—Not reported
Umeclidinium/​Vilanterol
—Trial running · NCT06474039

Trough FEV1, change

Aclidinium bromide/​formoterol fumarate
0.1 vs -0.0+0.1 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
Umeclidinium/​Vilanterol
0.2 vs 0.1vs TIO62.5/25 µg · wk 24 · n 400NCT01777334
3 other results
  • 0.1 vs -0.0 62.5/25 µg · wk 12.14 · n 224 · Phase 3 · primary NCT01899742
  • 0.2 vs 0.2 wk 12 · n 309 · Phase 3 · secondary NCT02487446
  • 0.2 vs 0.2 wk 12 · n 314 · Phase 3 · secondary NCT02487446

SGRQ total, change

Aclidinium bromide/​formoterol fumarate
-6.6 vs -2.2−4.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
4 other results
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
Umeclidinium/​Vilanterol
—Trial running · NCT06474039

TDI focal score

Aclidinium bromide/​formoterol fumarate
2.0 vs 0.6+1.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
  • 2.9 vs 2.1 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • 1.9 vs 1.9 wk 24 · n 353 · Phase 3 · secondary NCT01908140
Umeclidinium/​Vilanterol
—Trial running · NCT06474039
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Aclidinium bromide/formoterol fumarate: 4 of 4 rows · Umeclidinium/Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAclidinium bromide/​formoterol fumarateUmeclidinium/​Vilanterol
Dropout rate
19.5%400/12 μga
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
18.3%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.9%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
14.1%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
8.8%400/12 μg
NCT01462942 · Phase 3
10.5%400/6 μg
NCT01462942 · Phase 3
32.4%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
11.7%62.5/25 µga
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
—62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—
NCT02487446 · Phase 3 · registry result, not featured evidence
—27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
6.9%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
6.2%400/12 μga
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
6.5%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.1%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
4.7%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
3.1%400/12 μg
NCT01462942 · Phase 3
2.6%400/6 μg
NCT01462942 · Phase 3
6.6%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
4%62.5/25 µga
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
—62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—
NCT02487446 · Phase 3 · registry result, not featured evidence
—27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
2%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Serious AEs
5.7%400/12 μga
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
5.4%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.2%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
7.5%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
6%400/12 μg
NCT01462942 · Phase 3
4.7%400/6 μg
NCT01462942 · Phase 3
9.7%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
3.5%62.5/25 µga
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
1.7%62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
3.8%
NCT02487446 · Phase 3 · registry result, not featured evidence
5%27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
2.8%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
0.5%62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
400/12 μga
chronic obstructive pulmonary disease 15.2% (placebo 17.5%)
cough 5.1% (placebo 3.6%)
nasopharyngitis 4.8% (placebo 3.6%)
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
400/6 μg
chronic obstructive pulmonary disease 14.7% (placebo 17.5%)
nasopharyngitis 5.1% (placebo 3.6%)
cough 3.9% (placebo 3.6%)
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
upper respiratory tract infection 11.8% (placebo 8.9%)
chronic obstructive pulmonary disease 9.5% (placebo 13%)
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
chronic obstructive pulmonary disease 15%
headache 6%
nasopharyngitis 5.6%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
chronic obstructive pulmonary disease 8.6% (placebo 11.9%)
nasopharyngitis 7.8% (placebo 7.2%)
headache 7.5% (placebo 8.2%)
NCT01462942 · Phase 3
400/6 μg
chronic obstructive pulmonary disease 9.4% (placebo 11.9%)
nasopharyngitis 7.9% (placebo 7.2%)
headache 7.1% (placebo 8.2%)
NCT01462942 · Phase 3
400 μg/12 μg
chronic obstructive pulmonary disease 27%
urinary tract infection 6.6%
nasopharyngitis 6.4%
NCT01437540 · Phase 3 · registry result, not featured evidence
400/12 BID
protein urine present 15%
NCT03276078 · Phase 2 · registry result, not featured evidence
62.5/25 µga
headache 8.8%
nasopharyngitis 6.2%
cough 2.9%
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
62.5/25 µg once daily
nasopharyngitis 4%
headache 3.5%
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
chronic obstructive pulmonary disease 10.6%
nasopharyngitis 5.6%
oropharyngeal pain 2.9%
NCT02487446 · Phase 3 · registry result, not featured evidence
27.5/12.5 Bid
chronic obstructive pulmonary disease 14.8%
bronchitis 3.3%
sinusitis 1.8%
NCT02487498 · Phase 3 · registry result, not featured evidence
62.5/25 µg
nasopharyngitis 7.3%
headache 6.5%
NCT01899742 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 5%
NCT02014480 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aclidinium bromide/formoterol fumarate

FEV1 Change 1h 0.247 vs -0.037 placebo L @ 24wk400/12 μg
absolute change · L
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 4 more results
0.226 vs -0.037 placebo L @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.269 vs -0.03 placebo L @ 24wk400/12 μg
NCT01462942 · Phase 3
0.213 vs -0.03 placebo L @ 24wk400/6 μg
NCT01462942 · Phase 3
0.248 vs -0.05 placebo L @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
TDI Focal 2.017 vs 0.582 placebo score @ 24wk400/12 μg
absolute change · score
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
1.977 vs 0.582 placebo score @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
2.508 vs 1.215 placebo score @ 24wk400/12 μg
NCT01462942 · Phase 3
2.377 vs 1.215 placebo score @ 24wk400/6 μg
NCT01462942 · Phase 3
2.9 vs 2.1 placebo score @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
1.9 vs 1.9 Salmeterol / Fluticasone score @ 24wk
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
SGRQ Total -6.568 vs -2.215 placebo score @ 24wk400/12 μg
absolute change · score
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 4 more results
-5.942 vs -2.215 placebo score @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
-7.164 vs -6.511 placebo score @ 24wk400/12 μg
NCT01462942 · Phase 3
-8.339 vs -6.511 placebo score @ 24wk400/6 μg
NCT01462942 · Phase 3
-8.7 vs -4.7 placebo score @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 Peak 0.324 vs 0.008 placebo L @ 24wk400/12 μg
absolute change · L
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more result
1.655 vs 1.562 Salmeterol / Fluticasone L @ 24wk
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3

Umeclidinium/Vilanterol

FEV1 Wm0 6 h 0.276 vs 0.17 TIO L @ 24wk62.5/25 µg
absolute change · L
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 71.7% (n=173) vs 53.8% (n=171) UMEC @ 0wk62.5/25 µg once daily
responder rate · % of participants
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 · converted to % from 124 participants as posted
show 1 more result
51% (n=202) vs 40.1% (n=202) UMEC @ 0.14wk*62.5/25 µg
Responder
NCT02014480 · Phase 3 · registry result, not featured evidence · converted to % from 103 participants as posted
FEV1 AUC(0-24h 0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wk
absolute change · L
NCT02487446 · Phase 3 · registry result, not featured evidence
show 1 more result
0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wk
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 AUC 12-24h 0.2076 vs 0.2025 Umeclidinium/Vilanterol L @ 12wk
absolute change · L
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 AUC0-12h 0.2543 vs 0.2848 Umeclidinium/Vilanterol L @ 12wk
absolute change · L
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 Change 3 h 0.164 vs 0.091 Tiotropium Bromide L @ 12wk62.5/25 µg
absolute change · L
NCT01899742 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide/formoterol fumarate's landscape · Umeclidinium/Vilanterol's landscape